Skip to main content

MINI REVIEW article

Front. Endocrinol.
Sec. Pituitary Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1456922
This article is part of the Research Topic Progress in Diagnosis and Treatment of Hypothalamic & Pituitary Disorders View all 4 articles

Everolimus in pituitary tumor: a review of preclinical and clinical evidence

Provisionally accepted
Zihong Yao Zihong Yao 1,2Hui Chen Hui Chen 1*
  • 1 Department of Endocrinology and Metabolism, Lanzhou University Second Hospital, Lanzhou, China
  • 2 The Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu Province, China

The final, formatted version of the article will be published soon.

    Although pituitary tumors (PTs) are mostly benign, some PTs are characterized by low surgical resection rates, high recurrence rates, and poor response to conventional treatments and profoundly affect patients' quality of life. Everolimus (EVE) is the only FDA-approved mTOR inhibitor, which can be used for oral treatment. It effectively inhibits tumor cell proliferation and angiogenesis. It has been administered for various neuroendocrine tumors of the digestive tract, lungs, and pancreas. EVE not only suppresses the growth and proliferation of APT cells but also enhances their sensitivity to radiotherapy and chemotherapy. This review introduces the role of the PI3K/AKT/mTOR pathway in the development of APTs, comprehensively explores the current status of preclinical and clinical research of EVE in APTs, and discusses the blood-brain barrier permeability and safety of EVE.

    Keywords: everolimus1, pituitary tumor, PI3K/AKT/mTOR, Blood-Brain Barrier, Safety

    Received: 29 Jun 2024; Accepted: 27 Nov 2024.

    Copyright: © 2024 Yao and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hui Chen, Department of Endocrinology and Metabolism, Lanzhou University Second Hospital, Lanzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.